Phio Pharmaceuticals Corp (PHIO)

[sabaidii2]

Jan 8, 2018 Bio Showcase Conference presentation:
1) RXI-109 (Dermal Scarring): next step is Phase 2B testing (Slide #9, Audio 6:05)
In other words, not a runaway success as it's not ready for P3 testing.

2) RXI-231 (Skin Lightener)
Gel formulation was a significant step (Audio 7:30, Slide #11)

How well does RXI-231 works? Well, the 11/29/2017 PR states that on live, humans "show ... RXI-231 ... can reduce a change of skin tone triggered by UV".

The PR then immediately switches gear and talks about "in 3-dimensional reconstituted human epidermal culture" (ie, non-live human testing) it lasts "for one week after a single dose". And on the live humans? No mention. And how quickly does it take effect?

This PR was released on 11/29/2017 - more than enough time to shop it to cosmetic companies.

Verdict: Not looking good.

3) Samcyprone 2nd P2 readout due sometime in Q1-Q2 2018

Slide #14 summarizes dermatology Franchise. Looks positive (on paper), but who knows?

4) Ophthalmology: P1/2 Retinal Scarring readout due Q1 2018